MXPA06000018A - La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina. - Google Patents

La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina.

Info

Publication number
MXPA06000018A
MXPA06000018A MXPA06000018A MXPA06000018A MXPA06000018A MX PA06000018 A MXPA06000018 A MX PA06000018A MX PA06000018 A MXPA06000018 A MX PA06000018A MX PA06000018 A MXPA06000018 A MX PA06000018A MX PA06000018 A MXPA06000018 A MX PA06000018A
Authority
MX
Mexico
Prior art keywords
reuptake inhibitor
serotonin reuptake
serotonin
disorders
pharmaceutical composition
Prior art date
Application number
MXPA06000018A
Other languages
English (en)
Spanish (es)
Inventor
Sandra Willilgers
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33566216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA06000018(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MXPA06000018A publication Critical patent/MXPA06000018A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA06000018A 2003-07-04 2004-06-29 La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina. MXPA06000018A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301031 2003-07-04
US48547903P 2003-07-07 2003-07-07
PCT/DK2004/000464 WO2005002562A1 (en) 2003-07-04 2004-06-29 The combination of a serotonin reuptake inhibitors and agomelatine

Publications (1)

Publication Number Publication Date
MXPA06000018A true MXPA06000018A (es) 2006-03-21

Family

ID=33566216

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06000018A MXPA06000018A (es) 2003-07-04 2004-06-29 La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina.

Country Status (17)

Country Link
US (3) US20060205754A1 (enExample)
EP (1) EP1643985B1 (enExample)
JP (1) JP2007513052A (enExample)
KR (1) KR20060032598A (enExample)
CN (1) CN1852706A (enExample)
AR (1) AR047553A1 (enExample)
AT (1) ATE499096T1 (enExample)
AU (1) AU2004253225A1 (enExample)
BR (1) BRPI0411665A (enExample)
CA (1) CA2530880A1 (enExample)
DE (1) DE602004031527D1 (enExample)
DK (1) DK1643985T3 (enExample)
IL (1) IL172965A0 (enExample)
IS (1) IS8154A (enExample)
MX (1) MXPA06000018A (enExample)
NO (1) NO20060242L (enExample)
WO (1) WO2005002562A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2884714B1 (fr) * 2005-04-20 2011-05-06 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires
FR2890563B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent
FR2890564B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
WO2008035177A2 (en) * 2006-09-18 2008-03-27 Copharm Combination of mt1 and mt2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor
US7608737B2 (en) 2007-05-01 2009-10-27 Concert Pharmaceuticasl Inc. Naphthyl(ethyl)acetamides
WO2008141033A1 (en) * 2007-05-08 2008-11-20 Auspex Pharmaceuticals Inc. Substituted naphthalenes
FR2956031B1 (fr) * 2010-02-11 2012-03-02 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc)
WO2012054815A1 (en) 2010-10-22 2012-04-26 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
PL2517700T3 (pl) * 2011-04-28 2013-12-31 Zentiva Ks Farmaceutyczne dopuszczalne kokryształy n-[2-(7-metoksy-1-naftylo]acetamidu i sposoby ich wytwarzania
PH12012000132A1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
WO2013013060A1 (en) * 2011-07-19 2013-01-24 Lycus, Llc Agomelatine derivatives
EP2551257A1 (en) * 2011-07-28 2013-01-30 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of agomelatine with co-crystal-formers
WO2014024896A1 (ja) * 2012-08-08 2014-02-13 株式会社メドレックス アゴメラチンを含有する貼付剤組成物
WO2023154794A1 (en) * 2022-02-09 2023-08-17 University Of North Texas Health Science Center Drug repurposing for delayed treatment of ischemic stroke
CN116570579A (zh) * 2023-06-13 2023-08-11 深圳市泛谷药业股份有限公司 一种含有阿戈美拉汀和氟伏沙明的药物组合物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5470846A (en) * 1994-01-14 1995-11-28 Sandyk; Reuven Treatment of neurological and mental disorders
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
SE9703375D0 (sv) 1997-09-18 1997-09-18 Astra Ab A new combination
GB2336534A (en) * 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
CN1509169A (zh) * 2001-05-01 2004-06-30 H��¡�±������޹�˾ 对映体纯艾司西酞普兰的用途
US6617891B2 (en) * 2001-09-26 2003-09-09 Intel Corporation Slew rate at buffers by isolating predriver from driver
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine

Also Published As

Publication number Publication date
US20060205754A1 (en) 2006-09-14
NO20060242L (no) 2006-01-17
KR20060032598A (ko) 2006-04-17
CN1852706A (zh) 2006-10-25
US20130217776A1 (en) 2013-08-22
DE602004031527D1 (de) 2011-04-07
DK1643985T3 (da) 2011-06-06
ATE499096T1 (de) 2011-03-15
AR047553A1 (es) 2006-01-25
IL172965A0 (en) 2006-06-11
US20100267772A1 (en) 2010-10-21
AU2004253225A1 (en) 2005-01-13
JP2007513052A (ja) 2007-05-24
BRPI0411665A (pt) 2006-08-08
CA2530880A1 (en) 2005-01-13
WO2005002562A1 (en) 2005-01-13
EP1643985A1 (en) 2006-04-12
EP1643985B1 (en) 2011-02-23
IS8154A (is) 2005-11-28

Similar Documents

Publication Publication Date Title
US20100267772A1 (en) Combination of a Serotonin Reuptake Inhibitor and Agomelatine
HUP0203586A2 (hu) Szerotonin újrafelvétel inhibitorának, valamint 5-ht2c antagonistának, inverz agonistának vagy részleges agonistának a kombinációja
EP1545552B1 (en) Combination therapy wherein a serotonin reuptake inhibitor is used
Warneck et al. Action of (R)-sila-venlafaxine and reboxetine to antagonize cisplatin-induced acute and delayed emesis in the ferret
MXPA06002504A (es) Combinacion de un inhibidor de recaptacion de serotonina y loxapina.
JP2007513896A6 (ja) セロトニン再取り込み阻害剤およびヒスタミン３受容体アンタゴニスト、インバースアゴニストまたはパーシャルアゴニストの併用
JP2007513896A (ja) セロトニン再取り込み阻害剤およびヒスタミン３受容体アンタゴニスト、インバースアゴニストまたはパーシャルアゴニストの併用
US20070042014A1 (en) Combination of a serotonin reuptake inhibitor and loxapine
US20070066601A1 (en) Combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
KR20060066729A (ko) 우울증 치료를 위한 세로토닌 재흡수 억제제 및 글리신트랜스포터 타입 1 억제제의 조합
US20080167290A1 (en) Combination of a Serotonin Reuptake Inhibitor and Amoxapine
ZA200509588B (en) The combination of a serotonin reuptake inhibitors and agomelatine
CA2537757A1 (en) The combination of a serotonin reuptake inhibitor and amoxapine
MXPA06005127A (en) The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
CA2579520A1 (en) Combination therapy wherein a serotonin reuptake inhibitor is used
ZA200409278B (en) Combination therapy wherein a serotonin reuptake inhibitor is used

Legal Events

Date Code Title Description
FA Abandonment or withdrawal